RxDoctor Payments DataLook up a doctor →

Mary McFerren, PA

Medical · Shreveport, LANPI 1114924404

Payments from drug & device makers

$16,349in general payments, 2019–2025

Across 1,039 payments — averaging $15.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$4K
  • Biogen$1K
  • Genentech USA, Inc.$981
  • Neurocrine Biosciences, Inc.$975
  • Pfizer$869
  • Acadia Pharmaceuticals Inc$745
  • plus $8K from 33 others

What the payments were for

  • Consulting fees$1501%
  • Food & beverage$16,10498%
  • Education$951%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$16,349 in reported general payments places this provider in the 95th percentile of 253 medical providers in Louisiana.

See all medical providers in Louisiana

Medicare billing

Part B allowed, 2024
$95,900
Medicare patients
303
Services billed
8,318

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate12$97,179
NuplazidPimavanserin Tartrate16$80,205
Emgality PenGalcanezumab-Gnlm25$23,756
Oxtellar XrOxcarbazepine26$18,710
UbrelvyUbrogepant18$17,562
Nurtec OdtRimegepant Sulfate11$15,558
Aimovig AutoinjectorErenumab-Aooe15$10,872
TrileptalOxcarbazepine12$10,195
Dalfampridine ErDalfampridine21$8,351
Carbamazepine ErCarbamazepine29$4,241
Rivastigmine16$3,057
Carbidopa-Levodopa ErCarbidopa/Levodopa40$2,935
Oxcarbazepine27$2,840
Pyridostigmine Bromide34$1,958
Entacapone16$1,898

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$975$97,17912 claims
Acadia Pharmaceuticals IncNuplazid$745$80,20516 claims
AbbVieUbrelvy$3,699$17,56218 claims
PfizerNurtec Odt$869$15,55811 claims
Amneal Pharmaceuticals LLCPyridostigmine Bromide, Mycophenolate Mofetil$250$2,35745 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 253 medical providers in Louisiana.

Other medical in Shreveport

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →